. .. Resultats???????,

C. De-la-population-inclue and .. .. ,

.. .. Toxicité,

, Chirurgie

, Critère principal : survie sans progression

.. .. Survie-globale,

.. .. Toxicité,

C. De-rattrapage and ?. .. ,

D. ,

?. .. ,

, Comparaison du GETUG13 à notre étude

, Autres stratégies thérapeutiques adaptées à la décroissance des marqueurs tumoraux?????

. .. Traitements-de-rattrapage,

. .. Les-immunothérapies???,

.. .. ,

D. La and .. .. ,

T. .. Marqueurs-pronostiques-dans-les,

S. Culine, A. Kramar, and P. Biron, Chemotherapy in adult germ cell tumors, C Rev Oncol Hematol, vol.22, pp.229-263, 1996.

G. J. Bosl and R. J. Motzer, Testicular germ-cell cancer, N Engl J Med, vol.337, pp.242-253, 1997.

J. Beyer, P. Albers, and R. Altena, 5-The International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy, J Clin Oncol, vol.24, pp.4906-4911, 1997.

S. D. -williams, R. Birch, and L. H. Einhorn, Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide, N Engl J Med, vol.316, pp.1435-1440, 1987.

R. F. Ozols, D. C. Ihde, M. Linehan, and W. , A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors, J Clin Oncol, vol.6, pp.1031-1040, 1988.

C. R. -nichols, S. D. Williams, and P. J. Loehrer, Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol, J Clin Oncol, vol.9, pp.1163-1172, 1991.

J. P. Droz, A. Kramar, and P. Biron, Failure of high-dose cyclophosphamide and etoposide combined with doubledose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial, Eur Urol, vol.51, pp.739-746, 2007.

R. J. Motzer, C. J. Nichols, and K. A. Margolin, Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors, J Clin Oncol, vol.25, pp.247-256, 2007.

G. Daugaard, I. Skoneczna, and N. Aass, A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poorprognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974), Ann Oncol, vol.22, pp.1054-1061, 2011.

C. R. -nichols, P. J. Catalano, and E. D. Crawford, Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study, J Clin Oncol, vol.16, pp.1287-1293, 1998.

A. Gerl and W. Wilmanns, Antitumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor, Anticancer Drugs, vol.7, issue.6, pp.716-724, 1996.

A. B. Sandler, A. Cristou, S. Fox, S. D. Williams, C. R. Nichols et al., A phase II trial of paclitaxel in refractory germ cell tumors, Cancer, vol.82, issue.7, pp.1381-1387, 1998.

N. Panday, V. R. De-wit, R. Schornagel, J. H. Schot, M. Rosing et al., Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours, Cancer Chemother Pharmacol, vol.44, issue.4, pp.349-53, 1999.

R. De-wit, M. Louwerens, P. H. De-mulder, J. Verweij, S. Rodenhuis et al., Management of intermediateprognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP, Int J Cancer, vol.83, issue.6, pp.831-834, 1999.

R. J. Amato and D. M. Prow, Paclitaxel-based chemotherapy for patients with refractory or relapsed nonseminomatous germ cell tumors, Urol. Oncol, vol.5, issue.4, pp.134-138, 2000.

C. Bokemeyer, A. Gerl, P. Schoffski, A. Harstrick, N. Niederle et al., Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer, J Clin Oncol, vol.17, issue.2, pp.509-520, 1999.

P. Soulie, C. Garrino, M. A. Bensmaine, M. Bekradda, E. Brain et al., Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients, J Cancer Res Clin Oncol, vol.125, issue.12, pp.707-718, 1999.

C. Kollmannsberger, O. Rick, J. Beyer, G. Derigs, F. Mayer et al., Oxaliplatin in patients (pts) with cisplatin-refractory germ-cell cancer (GCT), Proc Am Soc Clin Oncol, vol.20, p.1295, 2001.

S. B. Kaye, G. M. Mead, and S. Fossa, Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study, J Clin Oncol, vol.16, pp.692-701, 1998.

S. Culine, A. Kramar, and C. Théodore, Randomized trial comparing bleomycin/ etoposide/ cisplatin with alternating cisplatin/ cyclophosphamide/ doxorubicin and vinblastine/ bleomycin regimens of chemotherapy for patients with intermediate-and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP, J Clin Oncol, vol.26, pp.421-427, 2008.

A. -lorch, A. Kleinhans, and A. Kramar, Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial, J Clin Oncol, vol.30, pp.800-805, 2012.

K. -fizazi and L. Zelek, « One cycle every 3 or 4 weeks »: is it obsolete? A review of dose-dense chemotherapy in solid neoplasms, Ann Oncol, vol.11, pp.133-149, 2000.

N. Lawrence, A. Martin, P. Vasey, and P. Grimison, Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Ann Oncol, 2016.

K. Fizazi, K. A. Do, and X. Wang, Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors, Br J Cancer, vol.86, pp.5904-5910, 1990.

A. Gerl, C. Clemm, R. Lamerz, K. Mann, W. Wilmanns et al., Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group, Clin Cancer Res, vol.29, pp.2032-2039, 1994.

K. -fizazi, S. Culine, and A. Kramar, Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors, J Clin Oncol, vol.22, pp.3868-3876, 2004.

K. -fizazi, S. Culine, and C. Logothetis, Filgrastim during combination chemotherapy of patients with poorprognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, J Clin Oncol, vol.15, issue.13, pp.716-740, 1998.

E. W. -steyerberg, H. J. Keizer, and J. Messemer, 39-Steyerberg EW, Gerl A, Fosså SD et coll. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer, J Clin Oncol, vol.79, pp.269-274, 1997.

K. 40-fizazi, S. Tjulandin, and C. Mahé, Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy. Results from an international study group, J Clin Oncol, vol.19, pp.2647-2657, 2001.

C. J. Logothetis, M. L. Samuels, A. Trinidade, F. Coll-;--andré, K. Fizazi et al., Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors, Eur J Cancer, vol.50, issue.27, p.6549, 2000.

F. Carneiro-ronchi, D. V. Araujo, and A. Urvanegia, José Augusto Rinck, J Clin Oncol, vol.36, 2018.

L. H. Einhorn, S. D. Williams, A. Chamness, M. J. Brames, S. M. Perkins et al., High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors, N Engl J Med, vol.357, issue.4, pp.340-348, 2007.

A. -lorch, A. Kleinhans, A. Kramar, C. K. Kollmannsberger, J. T. Hartmann et al., Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: longterm results of a prospective randomized trial, J Clin Oncol, vol.30, issue.8, pp.800-805, 2012.

D. R. Feldman, J. Sheinfeld, D. F. Bajorin, P. Fischer, S. Turkula et al., TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis, J Clin Oncol, vol.28, issue.10, pp.1706-1719, 2010.

C. Chevreau, C. Massard, A. Flechon, R. Delva, G. Gravis et al., Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial, Journal of Clinical Oncology, vol.35, issue.6_suppl, pp.4906-4917, 2010.

D. R. Feldman, A. Lorch, and A. Kramar, Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.34, issue.4, pp.345-51, 2016.

A. Bagrodia-;-adra, N. Althouse, S. K. Reddy, and N. , Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT), Germ Cell Tumors: Updates on Epidemiology, vol.35, 2017.

D. Raggi, P. Giannatempo, and . Apache, An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage, Clin Oncol, vol.36, 2018.

L. Jennewein, Y. -nieto, S. M. Tu, and M. T. Campbell, Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) +/-bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor risk relapsed germ-cell tumors (GCT), Curr Med Chem, vol.15, issue.6, pp.575-583, 2017.

A. Bezan, Risk stratification for venous thromboembolism in patients with testicular germ cell tumors, vol.12, p.176283, 2017.

M. J. Murray, Klaus-Peter Dieckmann and al. Targeted serum miRNA (TSmiR) test for diagnosis and followup of (testicular) germ cell cancer patients: A proof of principle, /AJCPOE11KEYZCJHT. 59-Ad J.M. Gillis, vol.135, pp.379-388, 2011.

J. Howard-lewin and R. Leao, Applying radiomics to predict pathology of post chemotherapy retroperitoneal nodal masses in germ cell tumors

, J Clin Oncol, vol.35, 2017.

T. Agthoven and L. Looijenga, Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test), Oncotarget, vol.8, issue.35, pp.58037-58086, 2017.

K. P. Dieckmann, A. Radtke, and M. Spiekermann, Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours, European urology, vol.71, issue.2, pp.213-233, 2017.

F. Pinto, F. M. Cárcano, E. Da-silva, D. O. Vidal, C. Scapulatempo-neto et al., Brachyury oncogene is a prognostic factor in high-risk testicular germ cell tumors, Andrology, vol.6, issue.4, pp.597-604, 2018.

J. Howard-lewin, A. ;--kvammen, O. Myklebust, T. A. Solberg, and A. , Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, American Society of Preventive Oncology, vol.25, issue.5, pp.773-782, 2016.

H. S. Haugnes, T. Wethal, N. Aass, O. Dahl, O. Klepp et al., Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study, Testosterone deficiency in testicular cancer survivors -a systematic review and meta-analysis, vol.28, pp.4649-57, 2010.

. Andrology, , vol.4, pp.382-390, 2016.

C. Fung, S. D. Fossa, M. T. Milano, J. Oldenburg, and L. B. Travis, Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study, J Clin Oncol, vol.31, issue.30, pp.3807-3821, 2013.

B. I. -drögemöller, Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients, Clin Cancer Res, vol.24, issue.8, pp.1866-1871, 2018.

J. J. -wheler, Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study, Cancer Res, vol.76, issue.13, pp.3690-701, 2016.

M. E. -dolan, 73-Hink Boer. Safety and usefulness of patient-centered shared survivorship care after chemotherapy for testicular cancer, Clin Cancer Res, vol.23, pp.5757-5768, 2017.